Twenty-four-hour intragastric acidity and clinical trial of bedtime enprostil 70 micrograms compared with ranitidine 300 mg in duodenal ulcer.

Abstract

The effects of bedtime 70 micrograms and twice daily 35 micrograms doses of enprostil on 24-hour intragastric acidity were investigated in nine duodenal ulcer patients in remission. Median nocturnal acidity decreased significantly by 30% with 35 micrograms twice daily, and by 48% with 70 micrograms at bedtime. In a clinical trial using bedtime dosing, 102 duodenal ulcer patients randomly received either ranitidine 300 mg or enprostil 70 micrograms. More ulcers healed after 4 and 8 weeks treatment with ranitidine than with enprostil (76% ranitidine vs 52% enprostil, at 4 weeks p = 0.0065 and 94% vs 68%, respectively at 8 weeks, P = 0.0007). However, 6 months after cessation of treatment there was no material difference in overall outcome. Despite combining mucosal protection with acid inhibition enprostil treatment conferred no advantage over simple acid inhibition.

• Authors: R P Walt, R E Pounder, C J Hawkey, I A Santana, K W Somerville, R F Logan, R G Long, M J Langman
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 1 Issue 2 Pg. 161-6 (Apr 1987) ISSN: 0269-2813 [Print] England
• PMID: 2979218 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Ranitidine
• Enprostil

Topics

• Adult
• Aged
• Circadian Rhythm
• Duodenal Ulcer (drug therapy, physiopathology)
• Enprostil (therapeutic use)
• Female
• Follow-Up Studies
• Gastric Acid (metabolism)
• Gastric Acidity Determination
• Humans
• Male
• Middle Aged
• Ranitidine (therapeutic use)